Latest News

  1. News: QFT-Plus highlighted in CAP TODAY!

    Earlier this week, CAP TODAY published an insightful article exploring the state of TB testing in the United States. The article draws on experiences from key opinion leaders at the US Mayo Clinic and surrounding hospitals and universities. You can read the article today – “TB testing: new approaches to old scourge”

  2. Press release: QIAGEN’s QuantiFERON-TB Gold Plus gains endorsement for latent tuberculosis screening in immigration

    QFT-Plus has been endorsed for immigration medical screening by the International Panel Physicians Association (IPPA).

  3. Press Release: QIAGEN welcomes WHO’s new global guidelines on latent TB screening

    World Health Organization recommends scale-up of preventive screening and treatment

  4. Press Release: QIAGEN welcomes new decision by U.S. Centers for Disease Control to use modern blood-based TB tests for immigration screening

    Gold-standard QuantiFERON-TB® Gold Plus cited as an FDA-approved option for testing

  5. Press Release: QIAGEN launches fourth-generation QuantiFERON®-TB Gold Plus in the U.S.

    NovelCD4/CD8 design delivers most comprehensive evaluation of patients’ immune response to tuberculosis infection.

  6. Press Release: QIAGEN’s QuantiFERON-TB Gold Plus gains U.S. FDA approval

    QIAGEN announces U.S. regulatory approval of QuantiFERON-TB Gold Plus (QFT-Plus) the fourth generation of the market leading blood test for detecting latent tuberculosis (TB) infection.

  7. Global Press Release: New research supporting QuantiFERON-TB Gold Plus

    This QIAGEN global press release describes new research studies suggesting the potential for additional clinical insights using QuantiFERON-TB Gold Plus.

Get in touch with QIAGEN
Follow QIAGEN on: